Home > Papers

 
 
The Application of the CM10 Proteinchip in the Diagnosis and Follow-up of Breast Cancer
Hu Yue 1 * #,Yu Jiekai 2 #
1.Department of Surgical Oncology, the Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, 310009
2.Cancer Institute, the Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, 310009
*Correspondence author
#Submitted by
Subject:
Funding: National Natural Science Foundation of China （No.No. 30801341）, The Research Fund for the Doctoral Program of Higher Education （No.No. 200803351107）
Opened online:28 February 2012
Accepted by: none
Citation: Hu Yue,Yu Jiekai.The Application of the CM10 Proteinchip in the Diagnosis and Follow-up of Breast Cancer[OL]. [28 February 2012] http://en.paper.edu.cn/en_releasepaper/content/4467650
 
 
Introduction: Breast cancer lacks good serum tumor markers for its diagnosis, follow-up and evaluation of curative effect. Our research aimed to use SELDI-TOF-MS and CM10 ProteinChip to detect the serum proteomic patterns in patients of breast cancer, screen the biomarker candidates, build and validate the diagnostic models and evaluate its clinical value in surveillance and follow-up after operation. Methods: SELDI-TOF-MS technology and CM10 ProteinChip were used to detect the serum proteomic patterns of 63 breast cancer patients and 40 healthy women. ZJU-PDAS software was used to screen the biomarker candidates and build the diagnostic models. The best model was blind validated in the subsequent-recruited 23 patients and 20 healthy women. Another 16 serum samples were detected to evaluate its significance in surveillance and follow-up after surgery. Results: The best model was composed by two protein peaks (3.9 KDa / BC1 and 5.6 KDa / BC2) with its sensitivity and specificity of 87.30% (55/63) and 95.00% (38/40) respectively. The sensitivity and specificity in the subsequent blind validation of new cases were 95.65% (22/23) and 85.00% (17/20) respectively. The diagnostic efficacies were the same to the patients of different stages (P>0.05). BC1's expression increased while BC2's decreased after operation (P<0.05). BC2's expression in the patients with recurrence or metastasis was higher than that in the tumor-free survivors (P<0.05). Conclusions: This method shows its potential in diagnosis, surveillance and follow-up after operation as well as screening of novel and better biomarkers in breast cancer.
Keywords:Breast neoplasm; SELDI-TOF; diagnosis; prognosis; bioinformatics; proteomics
 
 
 

For this paper
  • ● PDF (0B)
  • ● Revision 0 　　
  • ● Print this paper
  • ● Recommend this paper to a friend
  • ● Add to my favorite list

    Saved Papers

    Please enter a name for this paper to be shown in your personalized Saved Papers list

Tags
Add yours

Related Papers

Statistics
PDF Downloaded 205
Bookmarked 0
Recommend 5
Comments Array
Submit your papers